Ryan McDonald

The exploratory analysis may have showcased the benefit of testing for tertiary lymphoid structures.

“We found that black patients had lower odds of using telemedicine services,” said lead study author Jenny S. Guadamuz, PhD.

Lead study author Chung-Han Lee, MD, PhD, said that while the findings were “disappointing from a biomarker development standpoint,” the results confirm the effectiveness of the regimen across various lines of treatment.

There was limited clinical activity with the combination in patients with HRD-negative tumors.

The combination of the anti–PD-1 immunotherapy and the multikinase inhibitor also extended progression-free survival in the phase 3 KEYNOTE-581/CLEAR trial (Study 307).